Case Based - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Treatment of a Patient With Metastatic Gastrointestinal Stromal Tumor

Release Date: February 5, 2009
Expiration Date: February 5, 2010

Interactive Case Study Overview

The management of gastrointestinal stromal tumor (GIST) was markedly changed several years ago by scientific and clinical evidence supporting the integration of kinase-targeted agents into the treatment armamentarium. The management of GIST continues to evolve, with new indications for and clinical trial data on kinase-targeted and other biologic agents. The utilization of molecular assessments to identify patients at high risk of recurrence and to personalize their treatment regimen is becoming an integral part of the management of patients with both resectable and advanced disease. The need for standards in patient selection is underscored by the recent approval of kinase-targeted therapy for patients with resectable KIT+ disease.

The purpose of this activity is to update physicians on current standards regarding devising treatment strategies including kinase-targeted agents based on gross and molecular disease characteristics in patients with KIT+ GIST.

Target Audience

This educational activity is intended for medical oncologists involved in the care of patients with GIST. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.

Learning Objectives

Upon completion of this educational activity, you should be able to:

  • Assess data from a randomized clinical trial regarding the benefit of and patient selection for adjuvant therapy for resectable GIST
  • Summarize data from randomized clinical trials evaluating the efficacy and toxicity of targeted agents in patients with advanced GIST
  • Describe the impact of KIT mutations on devising therapeutic strategies for patients with advanced/metastatic GIST

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. Study the educational activity.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

Successful completion is determined by a score of 65% or greater.

View the Activity
You will be asked to login
or create an account.

Educational Grants

An educational grant for this activity was provided by:


  1. Novartis Oncology

Charles D. Blanke, MD, FACP, FRCPC
Systemic Therapy Provincial
   Program Leader
British Columbia Cancer Agency
Head, Division of Medical Oncology
University of British Columbia
Vancouver, British Columbia, Canada